![]() ![]() ![]() ![]() These weakening mutations limit the ability of the virus to cause infection but retain its ability to stimulate the body’s immune system sufficiently enough to elicit an amplified and effective response to combat the infection. This protein controls the balance of Herpes Simplex Virus latency and replication. Both the herpes vaccine candidates ( HerpaGreens & Herpesyl) are live-attenuated mutants of the herpes virus that could safely replicate and infect new cells at the site of injection.īoth the herpes vaccine candidates carry attenuating mutations in a key viral gene that encodes a protein named “infected cell protein 0” (ICP0). Two herpes vaccine candidates, RVx201 and RVx202 have been shown to be safe in a new pre-clinical study by researchers at the Department of Population Health Sciences, Virginia Tech, and the University of Oklahoma Health Sciences Center.
0 Comments
Leave a Reply. |